Itau Unibanco Holding S.A.’s ImmunityBio IBRX Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,734	Closed	-$36K	–	590
2022 Q2	$36K	Buy	9,734 +1,791	+23%	+$7.19K	﹤0.01%	341
2022 Q1	$45K	Hold	7,943	–	–	﹤0.01%	315
2021 Q4	$51K	Buy	7,943 +3,878	+95%	+$29.1K	﹤0.01%	281
2021 Q3	$40K	Buy	4,065 +1,394	+52%	+$15.3K	﹤0.01%	285
2021 Q2	$38K	Buy	+2,671	New	+$44.1K	﹤0.01%	231

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Itau Unibanco Holding S.A.'s IBRX Position: Q3 2022 in Review

Itau Unibanco Holding S.A. sold out of ImmunityBio (IBRX) in Q3 2022, closing a stake of 9,734 shares — an estimated $36K sold.

Itau Unibanco Holding S.A. first reported a position in IBRX in Q2 2021 and held it in 5 quarters. The position peaked at $51K in Q4 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

Itau Unibanco Holding S.A. reported no remaining ImmunityBio position as of Q3 2022 after selling out during the quarter.
Itau Unibanco Holding S.A. sold 9,734 ImmunityBio shares in Q3 2022, an estimated $36K.
Itau Unibanco Holding S.A. first reported a position in ImmunityBio in Q2 2021 and held it in 5 quarters.
Itau Unibanco Holding S.A.'s ImmunityBio position peaked at $51K in Q4 2021.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q3 2022, filed 14 Nov 2022.